Actuate Therapeutics, Inc. (ACTU) Drug Pipeline
| Drug Name | Condition | Stage | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Cyclophosphamide, Irinotecan, 9-Ing-41, Temozolomide, Topotecan | Refractory Cancer, Refractory Neoplasm, Neuroblastoma, Diffuse Intrinsic Pontine Glioma, Pediatric Lymphoma, Pediatric Brain Tumor, Refractory Tumor, Neuroblastoma Recurrent, Pediatric Cancer, Cancer Pediatric, Pediatric Meningioma | Phase I | Terminated | 9-ING-41 in Pediatric Patients With Refractory Malignancies. | Jan 20, 2020 | ― |
| Irinotecan, Lomustine, 9-Ing-41, Gemcitabine - 21 Day Cycle, Doxorubicin., Carboplatin., Nab Paclitaxel., Paclitaxel., Gemcitabine - 28 Day Cycle | Breast Neoplasms, Neoplasm Metastasis, Cancer, Pancreatic Cancer, Sarcoma, Pancreatic Neoplasms, Renal Cancer, Malignant Glioma, Pancreatic Adenocarcinoma, Pancreas Cancer, Neoplasm, Breast, Refractory Cancer, Bone Cancer, Malignancies, Neoplasms Pancreatic, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Resistant Cancer, Neoplasm Of Bone, Neoplasm Of Lung, Neoplasms,Colorectal, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Acute T Cell Leukemia Lymphoma | Phase II | Active Not Recruiting | 9-ING-41 in Patients with Advanced Cancers | Sep 15, 2018 | ― |
| Drug Name | Stage | Condition | Status | Study Name | Trial Start Date | Article |
|---|---|---|---|---|---|---|
| Cyclophosphamide, Irinotecan, 9-Ing-41, Temozolomide, Topotecan | Phase I | Refractory Cancer, Refractory Neoplasm, Neuroblastoma, Diffuse Intrinsic Pontine Glioma, Pediatric Lymphoma, Pediatric Brain Tumor, Refractory Tumor, Neuroblastoma Recurrent, Pediatric Cancer, Cancer Pediatric, Pediatric Meningioma | Terminated | 9-ING-41 in Pediatric Patients With Refractory Malignancies. | Jan 20, 2020 | ― |
| Irinotecan, Lomustine, 9-Ing-41, Gemcitabine - 21 Day Cycle, Doxorubicin., Carboplatin., Nab Paclitaxel., Paclitaxel., Gemcitabine - 28 Day Cycle | Phase II | Breast Neoplasms, Neoplasm Metastasis, Cancer, Pancreatic Cancer, Sarcoma, Pancreatic Neoplasms, Renal Cancer, Malignant Glioma, Pancreatic Adenocarcinoma, Pancreas Cancer, Neoplasm, Breast, Refractory Cancer, Bone Cancer, Malignancies, Neoplasms Pancreatic, Refractory Neoplasm, Refractory Non-Hodgkin Lymphoma, Resistant Cancer, Neoplasm Of Bone, Neoplasm Of Lung, Neoplasms,Colorectal, Malignancies Multiple, Bone Metastases, Bone Neoplasm, Acute T Cell Leukemia Lymphoma | Active Not Recruiting | 9-ING-41 in Patients with Advanced Cancers | Sep 15, 2018 | ― |
FAQ
What are the FDA phases for drug approval?
The FDA approval process for new drugs is divided into several phases: a. Preclinical testing b. Phase 1 – Safety and dosage c. Phase 2 – Effectiveness and side effects d. Phase 3 – Confirmation of effectiveness, monitoring of adverse reactions, and comparison with existing treatments e. Phase 4 – Post-marketing studies to track long-term safety and effectiveness
What is a clinical trial?
A clinical trial is a carefully designed study in which researchers test a drug, treatment, or medical device in people to evaluate its safety, effectiveness, and potential side effects. These trials are essential for determining whether a new treatment should be approved for widespread use.
What drugs does Actuate Therapeutics, Inc. (ACTU) have in its pipeline
Actuate Therapeutics, Inc. ACTU is currently developing the following drugs: Cyclophosphamide, Irinotecan, 9-Ing-41, Temozolomide, Topotecan, Irinotecan, Lomustine, 9-Ing-41, Gemcitabine - 21 Day Cycle, Doxorubicin., Carboplatin., Nab Paclitaxel., Paclitaxel., Gemcitabine - 28 Day Cycle. These drug candidates are in various stages of clinical development as the company works toward FDA approval.